



## Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

Amita Patnaik<sup>1</sup> · Michael Gordon<sup>2</sup> · Frank Tsai<sup>2</sup> · Kyriakos P. Papadopoulos<sup>1</sup> · Drew Rasco<sup>1</sup> · Muralidhar Beeram<sup>1</sup> · Siqing Fu<sup>3</sup> · Filip Janku<sup>3</sup> · Scott M. Hynes<sup>4</sup> · Sushma R. Gundala<sup>4</sup> · Melinda D. Willard<sup>4</sup> · Wei Zhang<sup>4</sup> · Aimee Bence Lin<sup>4</sup> · David Hong<sup>3</sup>

Published online: 16 July 2018  
© Springer-Verlag GmbH Germany, part of Springer Nature 2018

**Correction to: Cancer Chemotherapy and Pharmacology**  
<https://doi.org/10.1007/s00280-018-3623-7>

The original version of this article unfortunately contained a mistake. The co-authors' names were incorrect.

The correct names should be: Kyriakos P. Papadopoulos and Muralidhar Beeram.

---

The original article can be found online at <https://doi.org/10.1007/s00280-018-3623-7>.

---

✉ Amita Patnaik  
Amita.Patnaik@startsa.com

<sup>1</sup> South Texas Accelerated Research Therapeutics (START),  
4383 Medical Drive, Suite 4026, San Antonio, TX, USA

<sup>2</sup> HonorHealth Research Institute, Scottsdale, AZ, USA

<sup>3</sup> Cancer Medicine Division, MD Anderson Cancer Center,  
The University of Texas, Houston, TX, USA

<sup>4</sup> Eli Lilly and Company, Indianapolis, IN, USA